Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
T. André, C. Boni, L. Mounedji-Boudiaf, et al.. (2004). The New England journal of medicine. Cited 3,465 times. https://doi.org/10.1056/NEJMOA032709
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
R. Goldberg, D. Sargent, R. Morton, et al.. (2004). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Cited 2,290 times. https://doi.org/10.1200/JCO.2004.09.046
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
T. André, C. Boni, M. Navarro, et al.. (2009). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Cited 2,102 times. https://doi.org/10.1200/JCO.2008.20.6771
Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
T. André, A. de Gramont, D. Vernerey, et al.. (2015). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Cited 590 times. https://doi.org/10.1200/JCO.2015.63.4238
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.
C. Allegra, G. Yothers, M. O’connell, et al.. (2011). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Cited 580 times. https://doi.org/10.1200/JCO.2010.30.0855
Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial.
Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.
E. Díaz-Rubio, J. Tabernero, A. Gómez-España, et al.. (2007). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Cited 254 times. https://doi.org/10.1200/JCO.2006.09.8467
Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
R. Goldberg, D. Sargent, R. Morton, et al.. (2006). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Cited 231 times. https://doi.org/10.1200/JCO.2006.06.1317
UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy
Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer.
Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study.
E. Aranda, M. Valladares, M. Martínez-Villacampa, et al.. (2009). Annals of oncology : official journal of the European Society for Medical Oncology. Cited 20 times. https://doi.org/10.1093/annonc/mdn557
